Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)

被引：0

作者：

Berton-Rigaud, D. ^{[1
,2
]}

Pautier, P. ^{[3
,4
]}

Lorusso, D. ^{[5
,6
]}

Gennigens, C. ^{[7
]}

Gladieff, L. ^{[8
,9
]}

Kryzhanivska, A. ^{[10
]}

Bowman, J. ^{[11
]}

Tian, C. ^{[12
]}

Cornfeld, M.

Van Gorp, T. ^{[13
]}

机构：

[1] GINECO, Serv Oncol Med, St Herblain, France

[2] Inst Cancerol IOuest ICO, St Herblain, France

[3] GINECO, Dept Med, Villejuif, France

[4] Inst Gustave Roussy, Villejuif, France

[5] Fdn Policlin Univ Agostino Gemelli, Gynecol Oncol Unit, Rome, Italy

[6] Univ Cattolica Sacro Cuore, Rome, Italy

[7] Ctr Hosp Univ Sart Tilman, Oncol Gynecol Unit, Liege, Belgium

[8] GINECO, Med Oncol Dept, Toulouse, France

[9] Inst Claudius Regaud IUCT Oncopole, Toulouse, France

[10] Ivano Frankivsk Natl Med Univ, Gynecol Surg Dept, Ivano Frankivsk, Ukraine

[11] Incyte Corp, Immuno Oncol, Wilmington, DE USA

[12] Incyte Corp, Biostat, Wilmington, DE USA

[13] Univ Hosp Leuven, Leuven Canc Inst, Dept Gynaecol, Div Gynaecol Oncol, Leuven, Belgium

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.1934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

755P

引用

页码：S517 / S517

页数：1